Canaccord lowered the firm’s price target on Niagen Bioscience (NAGE) to $14 from $16 and keeps a Buy rating on the shares. The firm said they posted a Q3 beat as they continue to see strong demand for the flagship TruNiagen supplement businesses, leading to total company sales up +32.9% vs. our/Street estimate of +22.6%/+22.0%.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAGE: